Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 501–600 of 1,000
Neurocritical Care of a Reperfused Brain
Badruddin, A., Taqi, M. A., Abraham, M. G., Dani, D., & Zaidat, O. O. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0156-9 · Cited by 21
“Studies have shown that it prevents enlargement of hematoma but does not improve overall clinical outcome [ 36 ].”
BackgroundManagement of acquired coagulopathy in acute paediatrics
Morley, S. L. (2010) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2007.135749 · Cited by 21
The clinical management of acute intracerebral hemorrhage
Aiyagari, V. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1113876 · Cited by 24
Functional outcome prediction following intracerebral hemorrhage
Appelboom, G., Bruce, S. S., Han, J. E., Piazza, M. A., Hwang, B. Y., Hickman, Z. L., Zacharia, B. E., Carpenter, A., Monahan, A., Vaughan, K. A., et al. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.11.005 · Cited by 22
Anticoagulation-Related Intracranial Hemorrhages
Mittal, M. K., & Rabinstein, A. A. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0258-8 · Cited by 20
Outcome Trajectories after Intracerebral Hemorrhage
Carhuapoma, L., Murthy, S. B., & Shah, V. A. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1787104 · Cited by 23
Complications of recombinant activated human coagulation factor VII
Howes, J. L., Smith, R. S., Helmer, S. D., & Taylor, S. M. (2009) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.05.026 · Cited by 20
Prognostic Factors and Treatment Effect in the CHIMES Study
Chankrachang, S., Navarro, J. C., Silva, D. A. D., Towanabut, S., Chua, C. L., Lee, C. F., Venketasubramanian, N., Wong, K. S., Bousser, M., & Chen, C. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2014.11.017 · Cited by 20
“Such high response rate in the placebo arm and inclusion of subjects with prognostic heterogeneity have been shown to affect the potential of detecting treatment effects in clinical trials.(11,20,21) Indeed, our present analysis on the entire CHIMES cohort shows that MLC601 may be beneficial in patients with predicted…”
Legriel, S., Pico, F., Dinh, Y.-R. T., Lemiale, V., Bédos, J., Resche‐Rigon, M., & Cariou, A. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0159-z · Cited by 21
Liu, L., Wang, Y., Meng, X., Li, N., Tan, Y., Nie, X., Liu, D., & Zhao, X. (2017) · International Journal of Stroke · doi:10.1177/1747493017694394 · Cited by 20
Hong, D., Stradling, D., Dastur, C. K., Akbari, Y., Groysman, L. I., Al-Khoury, L., Chen, J. W., Small, S. L., & Yu, W. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00184 · Cited by 21
Preclinical Studies and Translational Applications of Intracerebral Hemorrhage
Siaw-Debrah, F., Nyanzu, M. K., Ni, H., Lin, X., Xu, Z., Ruan, L., Zhuge, Q., & Huang, L. (2017) · BioMed Research International · doi:10.1155/2017/5135429 · Cited by 22
Recent Advances in the Acute Management of Intracerebral Hemorrhage
Burns, J. D., Fisher, J. L., & Cervantes-Arslanian, A. M. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2017.11.005 · Cited by 22
Race/ethnicity influences outcomes in young adults with supratentorial intracerebral hemorrhage
Miyares, L. C., Falcone, G. J., Leasure, A. C., Adeoye, O. M., Shi, F., Kittner, S. J., Langefeld, C. D., Vagal, A. S., Sheth, K. N., & Woo, D. (2020) · Neurology · doi:10.1212/wnl.0000000000008930 · Cited by 20
“IVH extension 199 (48) 35 (36) 164 (51)”
Can perihaematomal radiomics features predict haematoma expansion?
Zhu, D., Zhang, M., Li, Q., Liu, J., Zhuang, Y., Chen, Q., Chen, C., Xiang, Y., Zhang, Y., & Yang, Y. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.03.003 · Cited by 24
CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) Trial
James, M. L., Troy, J. D., Nowacki, N., Komisarow, J. M., Swisher, C. B., Tucker, K., Hatton, K. W., Babi, M. A., Worrall, B. B., Andrews, C. M., et al. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01287-0 · Cited by 20
Xia, X., Ren, Q., Cui, J., Dong, H., Huang, Z., Jiang, Q., Guan, S., Huang, C., Yin, J., Xu, J., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6158 · Cited by 21
“Recent trials failed to improve outcomes for ICH therapies, despite a reduction in HE (18-20).”
BackgroundSimma, B., Höliner, I., & Luetschg, J. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-012-1863-9 · Cited by 20
Esper, R. C., Monteros-Estrada, I. E. D. L., la Torre-León, T. D., Rosales-Gutiérrez, A. O., & López, J. A. (2014) · Journal of Intensive Care · doi:10.1186/s40560-014-0047-2 · Cited by 20
“Other arterial thromboembolic events (such as retinal artery embolism, renal artery thrombosis, arterial thrombosis of limb, bowel infarction, and intestinal infarction) have also been reported [45-49].”
BackgroundZeng, L., Tang, G., Wang, J., Zhong, J., Xia, Z., Li, J.-X., Chen, G., Zhang, Y., Luo, S., Huang, G., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024932 · Cited by 23
“Three other influential RCT trials of medical treatments with drugs, including FAST, INTERACT2 and CHANT, that exhibit mechanisms very different from those of RBS used similar methods to evaluate the safety and efficacy and found no significant benefit.(17) 28 29 Data from the clinical study suggested that the adminis…”
McQuay, N., Cipolla, J., Franges, E. Z., & Thompson, G. (2009) · Journal of neurosurgery · doi:10.3171/2009.4.jns081611 · Cited by 20
Jakubovic, R. Y., & Aviv, R. I. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00086 · Cited by 20
Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage
Eilertsen, H., Menon, C. S., Law, Z. K., Chen, C., Bath, P. M., Steiner, T., Desborough, M., Sandset, E. C., Sprigg, N., & Salman, R. A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005951.pub5 · Cited by 19
Self-citationBlood Pressure Management in Intracerebral Haemorrhage: when, how much, and for how long?
Mutimer, C. A., Yassi, N., & Wu, T. Y. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01341-2 · Cited by 24
“Haemostatic therapy (recombinant factor VIIa [3, 4] or tranexamic acid [5, 6]) are not utilised in clinical practice with randomised trials showing variable effects on haematoma expansion, safety, functional outcome and mortality.”
MethodEligibility for Randomized Trials of Treatments Specifically for Intracerebral Hemorrhage
Fonville, A. F., Samarasekera, N., Hutchison, A., Perry, D., Roos, Y. B. W. E. M., & Salman, R. A. (2013) · Stroke · doi:10.1161/strokeaha.113.001493 · Cited by 19
Shinohara, Y., Yanagihara, T., Abe, K., Yoshimine, T., Fujinaka, T., Chuma, T., Ochi, F., Nagayama, M., Ogawa, A., Suzuki, N., et al. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.005 · Cited by 21
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation
Wang, S., Reeves, B., & Pawliński, R. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30369-3 · Cited by 21
The Safety of Recombinant Factor VIIa in Cardiac Surgery
Mitra, B., Phillips, L. E., Cameron, P. A., Billah, B., & Reid, C. M. (2010) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1003800409 · Cited by 19
Validation and Comparison of Noncontrast CT Scores to Predict Intracerebral Hemorrhage Expansion
Poli, L., Leuci, E., Costa, P., Giuli, V. D., Caria, F., Candeloro, E., Persico, A., Gamba, M., Magoni, M., Micieli, G., et al. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00797-2 · Cited by 20
Corry, J. J., Asaithambi, G., Shaik, A. P., Lassig, J. P., Marino, E. H., Ho, B. M., Castle, A. L., Banerji, N., & Tipps, M. E. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00911-9 · Cited by 19
Mehan, S., Jadaun, K. S., Sharma, A., & Siddiqui, E. M. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210726110021 · Cited by 23
Connor, D., Huynh, T. J., Demchuk, A. M., Dowlatshahi, D. D., Gladstone, D. J., Subramaniapillai, S., Symons, S. P., & Aviv, R. I. (2015) · Neurovascular Imaging · doi:10.1186/s40809-015-0010-1 · Cited by 19
“Prevention of expansion is an attractive therapeutic target however improved means for expansion prediction are needed to guide potential acute interventions [3, 4].”
BackgroundPharmacotherapy Pearls for Emergency Neurological Life Support
Brophy, G. M., & Human, T. (2017) · Neurocritical Care · doi:10.1007/s12028-017-0456-x · Cited by 19
“Recombinant activated factor VII (rFVIIa) was shown to decrease hematoma growth in non-coagulopathic ICH patients; however, no improvement in mortality was demonstrated in a large randomized trial, so it is not recommended in this patient population [54].”
BackgroundIntensive blood pressure reduction in acute intracerebral hemorrhage: A meta-analysis
Tsivgoulis, G. K., & Katsanos, A. H. (2015) · Neurology · doi:10.1212/wnl.0000000000001696 · Cited by 19
Broderick, J. P., Naidech, A. M., Elm, J. J., Toyoda, Ḱ., Dowlatshahi, D. D., Demchuk, A. M., Khatri, P., Steiner, T., Bath, P. M., Audebert, H. J., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00097-8 · Cited by 23
Self-citationWatanabe, G., Conching, A., Ogasawara, C. T., Chavda, V. K., Bin-Alamer, O., Haider, A. S., Priola, S. M., Sharma, M., Hoz, S. S., Chaurasia, B. K., et al. (2023) · Neurosurgical Review · doi:10.1007/s10143-023-02044-x · Cited by 18
Natural History, Pathophysiology, and Recent Management Modalities of Intraventricular Hemorrhage
Essibayi, M. A., Abdallah, O. I., Mortezaei, A., Zaidi, S. E., Vaishnav, D., Cherian, J., Parikh, G. Y., Altschul, D., & Labib, M. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231204582 · Cited by 19
Etiologies of Intracerebral Hematomas
Wang, Q. T., & Tuhrim, S. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0253-0 · Cited by 19
Christensen, M. C., Broderick, J. P., Vincent, C., Morris, S., & Steiner, T. (2009) · Cerebrovascular Diseases · doi:10.1159/000219298 · Cited by 22
“The aim of this study was to investigate country differences in the clinical outcomes after intracerebral hemorrhage (ICH). We follow previous approaches in ischemic stroke and adjust for differences in case mix and case management to isolate the effect of these variables and examine residual variation in clinical out…”
MethodSelf-citationSecondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy
Purrucker, J. C., Capper, D., Behrens, L., & Veltkamp, R. C. (2014) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2014.01.042 · Cited by 18
Sartori, M. T., Imbergamo, S., Zanon, E., Bonaccorso, G., Pittoni, G. M., Feltracco, P., Ori, C., Pagnan, A., & Cella, G. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609335909 · Cited by 18
“Several such experiences have been reported in various clinical settings, for example, life-threatening hemorrhage due to trauma, surgery, pregnancy, liver diseases, anticoagulant therapy, and intracerebral hemorrhage,(5-10) while only a limited number of randomized clinical trials have been published to date.(11-21)…”
BackgroundStroke Prevention, Treatment, and Rehabilitation
Spence, D., & Barnett, H. J. M. (2012) · Cited by 22
Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis
Lombardo, S. R., Millar, D. A., Jurkovich, G. J., Coimbra, R. S. M., & Nirula, R. (2018) · Trauma Surgery & Acute Care Open · doi:10.1136/tsaco-2017-000134 · Cited by 18
Nie, X., Liu, J., Liu, D., Zhou, Q. G., Duan, W., Pu, Y., Yang, Z., Wen, M., Sun, H., Wang, W., et al. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-000941 · Cited by 18
Berkhof, F. F., & Eikenboom, J. C. J. (2008) · Transfusion · doi:10.1111/j.1537-2995.2008.02001.x · Cited by 18
“5 (2-120) Criteria of massive blood loss, n (%)† 1.”
BackgroundClinical Syndromes and Management of Intracerebral Hemorrhage
Ko, S., Choi, H. A., & Lee, K. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0251-2 · Cited by 20
Management of acute intracerebral haemorrhage – an update
Law, Z. K., Appleton, J. P., Bath, P. M., & Sprigg, N. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-2-166 · Cited by 27
Naganuma, M., Toyoda, Ḱ., Nonogi, H., Yokota, C., Koga, M., Yokoyama, H., Okayama, A., Naritomi, H., & Minematsu, K. (2009) · Cerebrovascular Diseases · doi:10.1159/000215941 · Cited by 18
“failed to show an overall benefit from early surgery for ICH patients when compared with initial conservative treatment. These findings resulted in a relative increase in the role of medical therapies for acute ICH. Although the trial of efficacy and safety of recombinant activated factor VII for acute ICH failed [”
ResultKey Points to Consider When Evaluating Andexxa for Formulary Addition
Peled, H. B., Dau, N. Q., & Lau, H. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00866-6 · Cited by 19
Prediction of haematoma expansion with the CTA spot sign: a useful biomarker?
Wardlaw, J. M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70045-5 · Cited by 17
Anderson, C. S., & Qureshi, A. I. (2014) · Stroke · doi:10.1161/strokeaha.114.006321 · Cited by 17
Steiner, T., Vincent, C., Stephen Morris, A., Davis, S. M., Vallejo‐Torres, L., & Christensen, M. C. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.12.008 · Cited by 17
Self-citationAspirin Use or Reduced Platelet Activity Predicts Craniotomy After Intracerebral Hemorrhage
Naidech, A. M., Rosenberg, N. F., Bernstein, R. A., & Batjer, H. H. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9557-0 · Cited by 17
“Clinical studies of recombinant Factor VII excluded patients in whom surgical hematoma evacuation was planned [ 13 ], although Factor VII has been used in combination with early surgery [14].”
BackgroundRoh, D. J., Torres, G. L., Cai, C. C., Zammit, C., Reynolds, A. S., Mitchell, A., Connolly, E. S., Claassen, J., Grotta, J. C., Choi, H. A., et al. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa056 · Cited by 17
Zhang, M., Chen, J., Zhan, C., Liu, J., Chen, Q., Xia, T., Zhang, T., Zhu, D., Chen, C., & Yang, Y. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00334 · Cited by 17
Wang, H., Wu, J., Yang, X., Liu, J., Tao, W., Hao, Z., Wu, B., Liu, M., Zhang, S., & Wang, D. (2021) · BMC Neurology · doi:10.1186/s12883-021-02494-0 · Cited by 17
Tahara, S., Hattori, Y., Aso, S., Uda, K., Kumazawa, R., Matsui, H., Fushimi, K., Yasunaga, H., & Morita, A. (2022) · Neurocritical Care · doi:10.1007/s12028-022-01634-9 · Cited by 17
“Poor mRS was defined as severe disability (mRS grade 5) or death (mRS grade 6), as described in a previous report [28].”
MethodKarkouti, K., Arellano, R., Aye, T., Dupuis, J., Kent, B. A., Lee, T. W. R., Lin, Y., Ralley, F. E., MacAdams, C. L., Mazer, C. D., et al. (2014) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-014-0184-z · Cited by 17
“Thus, they have proposed that its off-label use should be confined to clinical trials.(6-9) On the C.”
Huber, A. W., Raio, L., Alberio, L., Ghezzi, F., & Surbek, D. (2011) · Journal of Perinatal Medicine · doi:10.1515/jpm.2011.109 · Cited by 17
Intracerebral Hemorrhage: Clinical Overview and Pathophysiologic Concepts
Rincón, F., & Mayer, S. A. (2012) · Translational Stroke Research · doi:10.1007/s12975-012-0175-8 · Cited by 18
Self-citationFibrinolytic therapy versus craniotomy for anticoagulant-associated intracerebral hemorrhage
Rohde, V., Uzma, N., Rohde, I., Clair, E. G. S., & Samadani, U. (2009) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2009.02.004 · Cited by 17
Transfusion practice in neuroanesthesia
McEwen, J., & Huttunen, K. T. H. (2009) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32832ff4a2 · Cited by 17
VanDerWerf, J. D., Kurowski, D., Siegler, J. E., Ganguly, T. M., & Cucchiara, B. L. (2018) · Neurocritical Care · doi:10.1007/s12028-018-0507-y · Cited by 17
Emergency Imaging of Intracerebral Haemorrhage
Alobeidi, F., & Aviv, R. I. (2015) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000437110 · Cited by 17
Management of Spontaneous Intracerebral Hematoma
Morioka, M., & Orito, K. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2016-0327 · Cited by 16
Tranexamic Acid Within 4.5 Hours of Intracerebral Hemorrhage With the CTA Spot Sign
Yassi, N., Yogendrakumar, V., Churilov, L. P., Meretoja, A., Wu, T. Y., Campbell, B. C. V., Strbian, D., Jeng, J., Woodhouse, L. J., Ovesen, C., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000210104 · Cited by 16
Self-citationShowing No Spot Sign Is a Strong Predictor of Independent Living after Intracerebral Haemorrhage
Havsteen, I. B., Ovesen, C., Christensen, A. F., Hansen, C. K., Nielsen, J. K., & Christensen, H. (2014) · Cerebrovascular Diseases · doi:10.1159/000357397 · Cited by 16
Christensen, M. C., & Morris, S. (2008) · Neurocritical Care · doi:10.1007/s12028-008-9124-5 · Cited by 19
“We use data from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, a recent multinational, placebo-controlled, clinical trial investigating the effect of recombinant activated factor VII (rFVIIa) for the treatment of spontaneous ICH [ 10 ].”
MethodPerioperative Management of Anticoagulation
Guha, D., & Macdonald, R. L. (2017) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2016.11.011 · Cited by 16
Top 100 Most-Cited Articles on Spontaneous Intracerebral Hemorrhage: A Bibliometric Analysis
Nasir, S. A. R., Gilani, J. A., Fatima, K., Faheem, U., Kazmi, O., Siddiqi, J., & Khosa, F. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.09.077 · Cited by 16
Management of Intracranial Hemorrhage in the Anticoagulated Patient
Macdonald, R. L. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.06.013 · Cited by 16
Anesthetic considerations for extracranial injuries in patients with associated brain trauma
Rath, G., Khandelwal, A., & Bithal, P. K. (2019) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_278_18 · Cited by 17
Red Blood Cell Microparticles Limit Hematoma Growth in Intracerebral Hemorrhage
Rehni, A. K., Cho, S., Quero, H. N., Shukla, V., Zhang, Z., Dong, C., Zhao, W., Pérez‐Pinzón, M. A., Koch, S., Jy, W., et al. (2022) · Stroke · doi:10.1161/strokeaha.122.039641 · Cited by 16
Neurological Impairment Among Survivors of Intracerebral Hemorrhage: The FAST Trial
Christensen, M. C., Stephen Morris, A., Vallejo‐Torres, L., Vincent, C., & Mayer, S. A. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9632-6 · Cited by 17
Self-citationA Rat Model of Intracerebral Hemorrhage Permitting Hematoma Aspiration plus Intralesional Injection
Sang, Y.-H., Liang, Y.-X., Liu, L.-G., Ellis-Behnke, R. G., Wu, W., So, K., & Cheung, R. T. F. (2013) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.62.63 · Cited by 17
“Clinical trials addressing a single pathogenic factor, such as hemorrhage volume or hematoma enlargement, have been successfully conducted, but clinical benefit cannot be shown [12, 13, 15, 18].”
BackgroundTransfusion Medicine and the Pregnant Patient
Lee, A. I., & Kaufman, R. M. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.02.002 · Cited by 17
Early management of acute cerebrovascular accident
Manners, J., Steinberg, A., & Shutter, L. (2017) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000462 · Cited by 20
Intracerebral hemorrhage: update and future directions
Rocha, E. C. A., Rouanet, C., Reges, D. S., Gagliardi, V. D. B., Singhal, A. B., & Silva, G. S. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20200088 · Cited by 22
Is a Prestroke Modified Rankin Scale Sensible?
Bruno, A., Switzer, J. A., Durkalski, V., & Nichols, F. T. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00661.x · Cited by 16
Blood Pressure in Intracerebral Hemorrhage — How Low Should We Go?
Frontera, J. A. (2013) · New England Journal of Medicine · doi:10.1056/nejme1305047 · Cited by 16
Treatment of intracerebral hemorrhage: What should we do now?
Wang, D. Z., & Talkad, A. V. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0003-z · Cited by 17
Controversies of Anticoagulation Reversal in Life-Threatening Bleeds
Rolfe, S., Papadopoulos, S., & Cabral, K. P. (2010) · Journal of Pharmacy Practice · doi:10.1177/0897190010362168 · Cited by 15
“Compared with placebo, Mayer et al found that 80 mcg/kg of rFVIIa was associated with a 5% absolute increase in the frequency of serious arterial thromboembolic events, despite the prospective exclusion of patients with thromboembolic disease (angina, claudication, DVT, cerebral infarction, or myocardial infarction) f…”
BackgroundInfluentialDabigatran etixilate and traumatic brain injury: Evolving anticoagulants require evolving care plans
Pakraftar, S. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i8.362 · Cited by 15
Advances in spontaneous intracerebral haemorrhage
Thanvi, B., Sprigg, N., & Munshi, S. K. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02925.x · Cited by 18
Nagasaka, T., Inao, S., & Wakabayashi, T. (2012) · Neurosurgical Review · doi:10.1007/s10143-012-0437-7 · Cited by 15
A prototype device for non-invasive continuous monitoring of intracerebral hemorrhage
Korfhagen, J. J., Kandadai, M. A., Clark, J. F., Adeoye, O. M., & Shaw, G. J. (2012) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2012.12.007 · Cited by 16
“This led to a phase III trial (Mayer et al., 2008) which also showed that treated patients had less hematoma expansion, but did not demonstrate improved mortality and morbidity.”
BackgroundManagement of Hepatic Encephalopathy
Frontera, J. A. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0297-2 · Cited by 16
Blood transfusion practices in neuroanaesthesia
Ali, Z., Hassan, N., & Syed, S. (2014) · Indian Journal of Anaesthesia · doi:10.4103/0019-5049.144670 · Cited by 15
“[17] The phase III results of Factor seven for acute haemorrhagic stroke (FAST) trial, showed that recombinant activated factor VII (rFVIIa) given within 4 h after the onset of symptoms of intracerebral haemorrhage significantly reduced growth of the haematoma but failed to improve survival or functional outcome at 90…”
Treatment of Coagulopathy in Intracranial Hemorrhage
Aguilar, M. I., & Freeman, W. D. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0061-1 · Cited by 20
“The US Food and Drug Administration (FDA) has approved rFVIIa for hemophiliac patients with factor inhibitors and bleeding emergencies, but not for use in the management of ICH, after a positive phase 2 trial [53] and a negative phase 3 trial [ 54 ].”
BackgroundThe role of recombinant-activated factor VII in bleeding trauma patients
Dutton, R. P., & Conti, B. M. (2009) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32832678c6 · Cited by 15
Zemrak, W. R., Smith, K., Rolfe, S., May, T., Trowbridge, R. L., Hayes, T. L., Grindlinger, G. A., & Seder, D. B. (2017) · Neurocritical Care · doi:10.1007/s12028-017-0422-7 · Cited by 16
Mao, J., Jiang, W., Liu, G., & Jiang, B. (2019) · British Journal of Neurosurgery · doi:10.1080/02688697.2019.1571162 · Cited by 15
“Many prognostic factors have been identified, such as the use of anticoagulant medications, autoimmune or infection that may reduce platelet amount or function, but the outcome of ICH is still poor.(3,4) The calcium is an essential nutrient for human body and plays an important role in cerebral injury after ICH.”
BackgroundThe puzzle of spontaneous versus traumatic intracranial hemorrhages
Quiñones-Ossa, G. A., Durango-Espinosa, Y. A., Padilla-Zambrano, H., Moscote‐Salazar, L. R., Keni, R. R., Deora, H., & Agrawal, A. (2020) · The Egyptian Journal of Neurosurgery : the official publication of the Egyptian Society of Neurological Surgeons/Egyptian journal of neurosurgery · doi:10.1186/s41984-020-00084-9 · Cited by 17
Management of Spontaneous Intracerebral Hemorrhage
Naval, N. S., Nyquist, P., & Carhuapoma, J. R. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.03.002 · Cited by 18
Löppönen, P., Tetri, S., Juvela, S., Huhtakangas, J., Saloheimo, P., Bode, M. K., Koivukangas, J. P., & Hillbom, M. (2013) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2012.12.022 · Cited by 15
Acute Stroke Therapy at the Crossroads
Broderick, J. P., & Meyers, P. M. (2011) · JAMA · doi:10.1001/jama.2011.1622 · Cited by 15
Self-citationWhat is the median volume of intracerebral hemorrhage and is it changing?
Robinson, D., Sanford, C. V., Kwon, S. Y., Coleman, E. R., Sekar, P., Murphy, R., Flaherty, M. L., Demel, S. L., Aziz, Y. N., Moomaw, C. J., et al. (2021) · International Journal of Stroke · doi:10.1177/17474930211032594 · Cited by 15
“1mL), despite few restrictions on inclusion.(12) This likely reflects the very narrow time window for enrollment in the trial (only patients with <3 h of symptoms), which selects for larger ICHs.”
BackgroundSelf-citationIronside, N. T., Patrie, J. T., Ng, S., Ding, D., Rizvi, T., Kumar, J. S., Mastorakos, P., Hussein, M. Z., Naamani, K. E., Abbas, R., et al. (2022) · Clinical Trials · doi:10.1177/17407745221105886 · Cited by 15
Yamamoto, T., Watabe, T., Yamashiro, S., Tokushige, K., Nakajima, N., Arakawa, Y., & Mine, Y. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.06.058 · Cited by 14
Recombinant factor VIIa as last‐resort treatment of desperate haemorrhage
Pálmason, R., Viðarsson, B., Sigvaldason, K., Ingimarsson, J. P., Guðbjartsson, T., Sigurðsson, G., & Onundarson, P. T. (2012) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2012.02688.x · Cited by 14
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.